228 related articles for article (PubMed ID: 24318096)
1. IGF2 DMR0 methylation, loss of imprinting, and patient prognosis in esophageal squamous cell carcinoma.
Murata A; Baba Y; Watanabe M; Shigaki H; Miyake K; Ishimoto T; Iwatsuki M; Iwagami S; Yoshida N; Oki E; Morita M; Nakao M; Baba H
Ann Surg Oncol; 2014 Apr; 21(4):1166-74. PubMed ID: 24318096
[TBL] [Abstract][Full Text] [Related]
2. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis.
Baba Y; Nosho K; Shima K; Huttenhower C; Tanaka N; Hazra A; Giovannucci EL; Fuchs CS; Ogino S
Gastroenterology; 2010 Dec; 139(6):1855-64. PubMed ID: 20682317
[TBL] [Abstract][Full Text] [Related]
3. H19 DMR methylation correlates to the progression of esophageal squamous cell carcinoma through IGF2 imprinting pathway.
Gao T; He B; Pan Y; Gu L; Chen L; Nie Z; Xu Y; Li R; Wang S
Clin Transl Oncol; 2014 Apr; 16(4):410-7. PubMed ID: 23943562
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA 91H contributes to the occurrence and progression of esophageal squamous cell carcinoma by inhibiting IGF2 expression.
Gao T; He B; Pan Y; Xu Y; Li R; Deng Q; Sun H; Wang S
Mol Carcinog; 2015 May; 54(5):359-67. PubMed ID: 24706416
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive methylation analysis of imprinting-associated differentially methylated regions in colorectal cancer.
Hidaka H; Higashimoto K; Aoki S; Mishima H; Hayashida C; Maeda T; Koga Y; Yatsuki H; Joh K; Noshiro H; Iwakiri R; Kawaguchi A; Yoshiura KI; Fujimoto K; Soejima H
Clin Epigenetics; 2018 Dec; 10(1):150. PubMed ID: 30509319
[TBL] [Abstract][Full Text] [Related]
6. LOI of IGF2 is associated with esophageal cancer and linked to methylation status of IGF2 DMR.
Xu W; Fan H; He X; Zhang J; Xie W
J Exp Clin Cancer Res; 2006 Dec; 25(4):543-7. PubMed ID: 17310846
[TBL] [Abstract][Full Text] [Related]
7. Somatically acquired hypomethylation of IGF2 in breast and colorectal cancer.
Ito Y; Koessler T; Ibrahim AE; Rai S; Vowler SL; Abu-Amero S; Silva AL; Maia AT; Huddleston JE; Uribe-Lewis S; Woodfine K; Jagodic M; Nativio R; Dunning A; Moore G; Klenova E; Bingham S; Pharoah PD; Brenton JD; Beck S; Sandhu MS; Murrell A
Hum Mol Genet; 2008 Sep; 17(17):2633-43. PubMed ID: 18541649
[TBL] [Abstract][Full Text] [Related]
8. Impairment of IGF2 gene expression in prostate cancer is triggered by epigenetic dysregulation of IGF2-DMR0 and its interaction with KLF4.
Schagdarsurengin U; Lammert A; Schunk N; Sheridan D; Gattenloehner S; Steger K; Wagenlehner F; Dansranjavin T
Cell Commun Signal; 2017 Oct; 15(1):40. PubMed ID: 29017567
[TBL] [Abstract][Full Text] [Related]
9. Loss of imprinting of insulin-like growth factor 2 is associated with increased risk of primary lung cancer in the central China region.
Zhang M; Wu CH; Zhu XL; Wang YJ
Asian Pac J Cancer Prev; 2014; 15(18):7799-803. PubMed ID: 25292066
[TBL] [Abstract][Full Text] [Related]
10. Loss of imprinting of IGF2 in fibroadenomas and phyllodes tumors of the breast.
Mishima C; Kagara N; Tanei T; Naoi Y; Shimoda M; Shimomura A; Shimazu K; Kim SJ; Noguchi S
Oncol Rep; 2016 Mar; 35(3):1511-8. PubMed ID: 26676988
[TBL] [Abstract][Full Text] [Related]
11. DNA methylation analysis of multiple imprinted DMRs in Sotos syndrome reveals IGF2-DMR0 as a DNA methylation-dependent, P0 promoter-specific enhancer.
Watanabe H; Higashimoto K; Miyake N; Morita S; Horii T; Kimura M; Suzuki T; Maeda T; Hidaka H; Aoki S; Yatsuki H; Okamoto N; Uemura T; Hatada I; Matsumoto N; Soejima H
FASEB J; 2020 Jan; 34(1):960-973. PubMed ID: 31914674
[TBL] [Abstract][Full Text] [Related]
12. [The expression and imprinting status of insulin-like growth factor 2 gene in colorectal cancer].
Zhang FR; He XB; Yang YH; Xie W
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Feb; 20(1):31-4. PubMed ID: 12579496
[TBL] [Abstract][Full Text] [Related]
13. Loss of imprinting and abnormal expression of the insulin-like growth factor 2 gene in gastric cancer.
Zuo QS; Yan R; Feng DX; Zhao R; Chen C; Jiang YM; Cruz-Correa M; Casson AG; Kang XD; Han F; Chen T
Mol Carcinog; 2011 May; 50(5):390-6. PubMed ID: 21268128
[TBL] [Abstract][Full Text] [Related]
14. Loss of imprinting of the insulin-like growth factor II (IGF2) gene in esophageal normal and adenocarcinoma tissues.
Zhao R; DeCoteau JF; Geyer CR; Gao M; Cui H; Casson AG
Carcinogenesis; 2009 Dec; 30(12):2117-22. PubMed ID: 19843644
[TBL] [Abstract][Full Text] [Related]
15. Alcohol, one-carbon nutrient intake, and risk of colorectal cancer according to tumor methylation level of IGF2 differentially methylated region.
Nishihara R; Wang M; Qian ZR; Baba Y; Yamauchi M; Mima K; Sukawa Y; Kim SA; Inamura K; Zhang X; Wu K; Giovannucci EL; Chan AT; Fuchs CS; Ogino S; Schernhammer ES
Am J Clin Nutr; 2014 Dec; 100(6):1479-88. PubMed ID: 25411283
[TBL] [Abstract][Full Text] [Related]
16. Chromosomal instability associated with global DNA hypomethylation is associated with the initiation and progression of esophageal squamous cell carcinoma.
Kawano H; Saeki H; Kitao H; Tsuda Y; Otsu H; Ando K; Ito S; Egashira A; Oki E; Morita M; Oda Y; Maehara Y
Ann Surg Oncol; 2014 Dec; 21 Suppl 4():S696-702. PubMed ID: 24898425
[TBL] [Abstract][Full Text] [Related]
17. Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer.
Bhusari S; Yang B; Kueck J; Huang W; Jarrard DF
Prostate; 2011 Nov; 71(15):1621-30. PubMed ID: 21432864
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression.
Dejeux E; Olaso R; Dousset B; Audebourg A; Gut IG; Terris B; Tost J
Endocr Relat Cancer; 2009 Sep; 16(3):939-52. PubMed ID: 19502451
[TBL] [Abstract][Full Text] [Related]
19. Post-weaning diet affects genomic imprinting at the insulin-like growth factor 2 (Igf2) locus.
Waterland RA; Lin JR; Smith CA; Jirtle RL
Hum Mol Genet; 2006 Mar; 15(5):705-16. PubMed ID: 16421170
[TBL] [Abstract][Full Text] [Related]
20. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer.
Murphy SK; Huang Z; Wen Y; Spillman MA; Whitaker RS; Simel LR; Nichols TD; Marks JR; Berchuck A
Mol Cancer Res; 2006 Apr; 4(4):283-92. PubMed ID: 16603642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
